Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 26,837 Shares of Stock

Solid Biosciences Inc. (NASDAQ:SLDB) CFO Kevin Tan sold 26,837 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $172,830.28. Following the completion of the sale, the chief financial officer owned 108,984 shares of the company’s stock, valued at $701,856.96. The trade was a 19.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kevin Tan also recently made the following trade(s):

• On Tuesday, January 13th, Kevin Tan sold 5,704 shares of Solid Biosciences stock. The shares were sold at an average price of $5.27, for a total value of $30,060.08.

Solid Biosciences Price Performance

Shares of Solid Biosciences stock opened at $6.43 on Tuesday. The stock has a market cap of $500.96 million, a price-to-earnings ratio of -2.58 and a beta of 2.67. The firm’s 50-day moving average is $5.75 and its 200 day moving average is $5.71. Solid Biosciences Inc. has a 1 year low of $2.41 and a 1 year high of $7.37.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, equities analysts expect that Solid Biosciences Inc. will post -2.84 EPS for the current fiscal year.

Institutional Trading of Solid Biosciences

Several hedge funds have recently modified their holdings of the business. Bollard Group LLC bought a new stake in Solid Biosciences during the second quarter valued at $1,761,000. Geode Capital Management LLC lifted its stake in Solid Biosciences by 184.5% during the second quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock valued at $7,356,000 after buying an additional 979,294 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Solid Biosciences by 28.9% in the second quarter. Franklin Resources Inc. now owns 1,599,173 shares of the company’s stock valued at $7,788,000 after purchasing an additional 358,473 shares in the last quarter. Blair William & Co. IL purchased a new position in Solid Biosciences during the second quarter valued at approximately $807,000. Finally, ProShare Advisors LLC bought a new stake in shares of Solid Biosciences in the 2nd quarter valued at approximately $80,000. 81.46% of the stock is owned by institutional investors and hedge funds.

Solid Biosciences News Summary

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Analysts maintain a constructive view — SLDB has an average analyst rating of “Moderate Buy,” which may support demand despite near-term weakness. Analyst Rating Article
• Neutral Sentiment: Technical/market context is mixed — trading volume is slightly above average and the share price is within its 52-week range ($2.41–$7.37), suggesting limited directional conviction from broader market participants. (Market data referenced.)
• Negative Sentiment: Large, concurrent insider selling — multiple senior executives (CEO Alexander Cumbo, COO David Howton, CTO Paul Herzich, CFO Kevin Tan and other insiders) sold sizable positions on Feb 2 at an average price of $6.44. Combined disclosed sales total roughly 226k shares for about $1.45M, with individual position reductions in the ~20–25% range — a signal that could weigh on investor sentiment and share demand. Representative SEC filings: CEO Filing CTO Filing

Analysts Set New Price Targets

Several analysts have recently commented on SLDB shares. Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Barclays set a $9.00 price target on shares of Solid Biosciences and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Wednesday, January 14th. Chardan Capital reiterated a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a research report on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.70.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.